Literature DB >> 35279736

Dihydroartemisinin ameliorates chronic nonbacterial prostatitis and epithelial cellular inflammation by blocking the E2F7/HIF1α pathway.

Yan Zhou1, Jun-Hao Wang1, Jian-Peng Han1, Jian-Yong Feng1, Kuo Guo1, Fei Du1, Wen-Bin Chen1, Yong-Zhang Li2.   

Abstract

OBJECTIVE: Chronic nonbacterial prostatitis (CNP) has remained one of the most prevalent urological diseases, particularly in older men. Dihydroartemisinin (DHA) has been identified as a semi-synthetic derivative of artemisinin that exhibits broad protective effects. However, the role of DHA in inhibiting CNP inflammation and prostatic epithelial cell proliferation remains largely unknown.
MATERIALS AND METHODS: CNP animal model was induced by carrageenan in C57BL/6 mouse. Enzyme linked immunosorbent assay (ELISA), Real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot were used to examine inflammatory cytokines and proliferation genes expression. Immunofluorescence and immunochemistry staining were used to detect and E2F7 expression. Human prostatic epithelial cells (HPECs) and RWPE-1 was induced by lipopolysaccharide (LPS) to mimic CNP model in vitro. Cell proliferation was determined using MTS assay.
RESULTS: DHA significantly alleviated the rough epithelium and inhibited multilamellar cell formation in the prostatic gland cavity and prostatic index induced by carrageenan. In addition, DHA decreased the expression of TNF-α and IL-6 inflammatory factors in prostatitis tissues and in LPS-induced epithelial cells. Upregulation of transcription factor E2F7, which expression was inhibited by DHA, was found in CNP tissues, human BPH tissues and LPS-induced epithelial cells inflammatory response. Mechanically, we found that depletion of E2F7 by shRNA inhibited epithelial cell proliferation and LPS-induced inflammation while DHA further enhance these effects. Furthermore, HIF1α was transcriptional regulated by E2F7 and involved in E2F7-inhibited CNP and cellular inflammatory response. Interestingly, we found that inhibition of HIF1α blocks E2F7-induced cell inflammatory response but does not obstruct E2F7-promoted cell growth.
CONCLUSION: The results revealed that DHA inhibits the CNP and inflammation by blocking the E2F7/HIF1α pathway. Our findings provide new evidence for the mechanism of DHA and its key role in CNP, which may provide an alternative solution for the prevention and treatment of CNP.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Chronic nonbacterial prostatitis; Dihydroartemisinin; E2F7; Inflammation; Proliferation

Mesh:

Substances:

Year:  2022        PMID: 35279736     DOI: 10.1007/s00011-022-01544-8

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  5 in total

Review 1.  Common Questions About Chronic Prostatitis.

Authors:  James D Holt; W Allan Garrett; Tyler K McCurry; Joel M H Teichman
Journal:  Am Fam Physician       Date:  2016-02-15       Impact factor: 3.292

2.  Trans-perineal pumpkin seed oil phonophoresis as an adjunctive treatment for chronic nonbacterial prostatitis.

Authors:  Sayed A Tantawy; Hany Mi Elgohary; Dalia M Kamel
Journal:  Res Rep Urol       Date:  2018-09-18

3.  Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".

Authors:  Haitang Yang; Sean R R Hall; Beibei Sun; Feng Yao
Journal:  Br J Cancer       Date:  2020-12-18       Impact factor: 7.640

4.  Dynamic NF-κB and E2F interactions control the priority and timing of inflammatory signalling and cell proliferation.

Authors:  John M Ankers; Raheela Awais; Nicholas A Jones; James Boyd; Sheila Ryan; Antony D Adamson; Claire V Harper; Lloyd Bridge; David G Spiller; Dean A Jackson; Pawel Paszek; Violaine Sée; Michael Rh White
Journal:  Elife       Date:  2016-05-17       Impact factor: 8.140

Review 5.  Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy.

Authors:  Gianni Paulis
Journal:  Res Rep Urol       Date:  2018-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.